- Nordic Nanovector - Mature Data from the LYMRIT 37-01 - Part A trial, Published in Blood Advances
- Nordic Nanovector to Present at Upcoming Pareto Securities 11 th Healthcare Conference
- Nordic Nanovector ASA: Results for the Second Quarter and First Half 2020
- Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast - correction
- Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2020 Results Presentation and Webcast
- Nordic Nanovector Appoints Dr Christine Wilkinson Blanc as Chief Medical Officer
- Independent Review Committee Recommends Nordic Nanovector to focus on one dosage arm for the Pivotal PARADIGME Phase 2b Trial in Patients with 3L R/R FL
- Nordic Nanovector Announces EU Patent Granted Covering the Use of Alpha37
- Nordic Nanovector ASA - Share Capital Increase Registered
- Nordic Nanovector ASA: Allocation of Restricted Stock Unites (RSUs) to the Board of Directors
Nordic Nanovector ASA (8NN:STU) closed at 1.93, 117.25% above the 52 week low of 0.887 set on Mar 19, 2020.
0.887Mar 19 20203.40Dec 27 2019
Markit short selling activity
|Market cap||1.44bn NOK|
|EPS (TTM)||-7.20 |
Data delayed at least 15 minutes, as of Sep 21 2020.